DK0686030T3 - Med antigen ladede mikropartikler og farmaceutiske sammensætninger, som indeholder disse mikropartikler - Google Patents

Med antigen ladede mikropartikler og farmaceutiske sammensætninger, som indeholder disse mikropartikler

Info

Publication number
DK0686030T3
DK0686030T3 DK95903221T DK95903221T DK0686030T3 DK 0686030 T3 DK0686030 T3 DK 0686030T3 DK 95903221 T DK95903221 T DK 95903221T DK 95903221 T DK95903221 T DK 95903221T DK 0686030 T3 DK0686030 T3 DK 0686030T3
Authority
DK
Denmark
Prior art keywords
microparticles
antigen
biodegradable
potentiation
immunological
Prior art date
Application number
DK95903221T
Other languages
Danish (da)
English (en)
Inventor
Bruno Gander
Giampietro Corradin
Ying Men
Claudio Thomasin
Hans Peter Merkle
Original Assignee
Rmf Dictagene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rmf Dictagene Sa filed Critical Rmf Dictagene Sa
Application granted granted Critical
Publication of DK0686030T3 publication Critical patent/DK0686030T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
DK95903221T 1993-12-23 1994-12-23 Med antigen ladede mikropartikler og farmaceutiske sammensætninger, som indeholder disse mikropartikler DK0686030T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH384993 1993-12-23
PCT/CH1994/000242 WO1995017167A1 (de) 1993-12-23 1994-12-23 Verfahren zur potenzierung der immunologischen antwort

Publications (1)

Publication Number Publication Date
DK0686030T3 true DK0686030T3 (da) 2001-06-25

Family

ID=4264801

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95903221T DK0686030T3 (da) 1993-12-23 1994-12-23 Med antigen ladede mikropartikler og farmaceutiske sammensætninger, som indeholder disse mikropartikler

Country Status (12)

Country Link
US (1) US6596278B2 (es)
EP (1) EP0686030B1 (es)
JP (1) JPH08507088A (es)
KR (1) KR100372375B1 (es)
CN (1) CN1120809A (es)
AT (1) ATE199316T1 (es)
AU (1) AU1217395A (es)
CA (1) CA2156718A1 (es)
DE (1) DE59409668D1 (es)
DK (1) DK0686030T3 (es)
ES (1) ES2156932T3 (es)
WO (1) WO1995017167A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
EP0965336A1 (en) 1995-11-09 1999-12-22 Microbiological Research Authority Microencapsulated DNA for gene therapy
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
WO1999002183A2 (en) * 1997-07-10 1999-01-21 Ctl Immunotherapies Corporation A method of inducing a ctl response
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
WO1999065531A1 (en) 1998-06-18 1999-12-23 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
ATE452651T1 (de) 1998-09-01 2010-01-15 Merrion Res Iii Ltd Orale impfstoff-zusammensetzung
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
EP2351576A1 (en) * 2004-12-29 2011-08-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
US8202523B2 (en) * 2005-09-22 2012-06-19 ProSci, Inc. Glycosylated polypeptides produced in yeast mutants and methods of use thereof
JP2009512729A (ja) * 2005-10-24 2009-03-26 スタヴァル ファーマ リミテッド 菌類及び細菌を処理、抑制、殺滅する方法
AR064862A1 (es) * 2007-01-15 2009-04-29 Glaxosmithkline Biolog Sa Proteinas de fusion que comprenden un antigeno de rechazo tumoral prame (dage)
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
EP2575869B1 (en) * 2010-06-04 2017-07-26 Flow Pharma Inc. Peptide particle formulation
CN102901814B (zh) * 2012-07-12 2014-11-26 浙江大学 莠去津分子印迹金标试纸条及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5762965A (en) * 1984-03-16 1998-06-09 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradble-biocompatible microspheres
US4803070A (en) 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
JP3233402B2 (ja) 1989-11-13 2001-11-26 サイオス ノバ インコーポレイテッド 物質の制御送達用のリポスフェア
AU8303691A (en) * 1991-04-24 1992-12-21 United States Of America, As Represented By The Secretary Of The Army, The Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
WO1994015635A1 (en) * 1993-01-11 1994-07-21 Dana-Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
US5879687A (en) * 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
DK0991403T3 (da) 1997-01-30 2003-07-28 Chiron Corp Anvendelse af mikropartikler med adsorberet antigen til stimulering af immunresponser
US6312731B1 (en) 1997-08-29 2001-11-06 Southern Research Institute Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
PT1042001E (pt) 1997-12-16 2002-09-30 Chiron Corp Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua
ATE322285T1 (de) 1998-09-01 2006-04-15 Elan Corp Plc Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff- zusammensetzungen dazu

Also Published As

Publication number Publication date
KR960700692A (ko) 1996-02-24
DE59409668D1 (de) 2001-04-05
EP0686030B1 (de) 2001-02-28
AU1217395A (en) 1995-07-10
CN1120809A (zh) 1996-04-17
CA2156718A1 (en) 1995-06-29
US20020041879A1 (en) 2002-04-11
ES2156932T3 (es) 2001-08-01
US6596278B2 (en) 2003-07-22
EP0686030A1 (de) 1995-12-13
ATE199316T1 (de) 2001-03-15
WO1995017167A1 (de) 1995-06-29
KR100372375B1 (ko) 2003-04-21
JPH08507088A (ja) 1996-07-30

Similar Documents

Publication Publication Date Title
DK0686030T3 (da) Med antigen ladede mikropartikler og farmaceutiske sammensætninger, som indeholder disse mikropartikler
Stacey et al. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
DE69810459T2 (de) Reagenzien zur impfung, die eine cd8 t-zell-immunantwort erzeugen
DK0678034T3 (da) Induktion af cytotoksiske T-lymfocytreaktioner
CA2172507A1 (en) Methods and compositions for microencapsulation of antigens for use as vaccines
DK0946624T3 (da) Administrationssystem med biologisk nedbrydelige mikropartikler, som kan målrettes
CA2033640A1 (en) Vaccines against cancer and infectious diseases
CA2272338A1 (en) Immunization of infants
WO2001079259A8 (en) Javelinization of protein antigens to heat shock proteins
AU9215101A (en) Vaccines containing ribavirin and methods of use thereof
CA2137638A1 (en) Anti Gangliosides Monoclonal Antibodies and Their Use in the Specific Active Immunotherapy of Malignant Tumors
EP2057999A3 (en) Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
BR0010711A (pt) Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
KR100218138B1 (en) Methods and vaccines comprising surface-active copolymers
DE3854591D1 (de) Impfstoffe, deren charakteristischer Epitop in einem Picornavirusprotein, insbesondere Poliovirus, inkorporiert ist.
CA2128247A1 (en) Vaccines based on streptokinase
BR9306187A (pt) Vacina bacterin-toxóide pasteurella haemolytica tipo a-1
Lovgren Construction and potential of the iscom as immunogen.
HU9900534D0 (en) Aviadenovirus
Barber Antigenic structure of Salmonella paratyphi A grown on artificial media.
Himeno et al. Effects of carrageenan and dextran sulfate on the expression and development of delayed hypersensitivity
Fedorovskaya et al. Immune response of the body of donors to pyocyaneus antigen formerly hyperimmunized with staphylococcal anatoxine.
Zourbas et al. Immunization of dental surgeons against hepatitis B virus infection.
Dima et al. Oral immunization of the newly born guinea pig with dysenteric vaccine irradiated with gamma radiations( super (60) Co).